Stay updated on Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page.

Latest updates to the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page
- Check6 days agoChange DetectedThe page's revision metadata was updated, adding new last update dates (2026-08-31, 2027-06-30, 2028-05-31) and a new revision identifier (v3.6.6). The older revision marker (v3.6.5) appears to have been superseded.SummaryDifference0.2%

- Check13 days agoChange DetectedAdditional funding information was added to the study record, listing a 2017 U.S. NIH grant/contract. This update clarifies the NIH support behind the trial and its funding source.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page now displays revision v3.6.5, replacing the previous v3.6.4, indicating a version update of the study details page.SummaryDifference0.0%

- Check48 days agoChange DetectedThe revision label was updated from v3.6.3 to v3.6.4, indicating a new release version without altering the displayed study details.SummaryDifference0.0%

- Check56 days agoChange DetectedAdded a new PubMed publication entry for Shitara et al. on first-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma. The citation shows Nat Med 2026 Jun;32(6):2182-2190 with an Epub date of 2026 Mar 16, replacing the earlier Online ahead of print note.SummaryDifference0.0%

- Check70 days agoChange DetectedRevision tag updated to v3.6.3, replacing the previous v3.6.0 on the page. This indicates a new site revision without altering study details.SummaryDifference0.0%

Stay in the know with updates to Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page.